Synergy Pharmaceuticals, Inc. (SGYP)
-NasdaqGM 5.16 
0.05(0.98%) May 24, 4:00PM EDT|After Hours
:
5.16 0.00 (0.02%) May 24, 4:36PM EDT
| Prev Close: | 5.11 |
|---|
| Open: | 5.12 |
|---|
| Bid: | 4.98 x 500 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 14.30 |
|---|
| Beta: | 0.38 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 5.01 - 5.20 |
|---|
| 52wk Range: | 2.98 - 7.44 |
|---|
| Volume: | 351,303 |
|---|
| Avg Vol (3m): | 1,018,910 |
|---|
| Market Cap: | 465.34M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.77 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Positive Data from Synergy PharmaZacks(Fri May 24)
- 4 Healthcare Stock Stories For Tuesday Investment Wellnessat Wall St. Cheat Sheet(Tue May 21)
- Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatideat Seeking Alpha(Tue May 21)
- Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013GlobeNewswire(Tue May 21)
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Tue May 21)
- SYNERGY PHARMACEUTICALS, INC. FinancialsEDGAR Online Financials(Fri May 17)
- Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager Finny Kuruvilla Discusses His Portfolio Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu May 16)
- Synergy Pharma Posts Wider LossZacks(Wed May 15)
- Synergy Pharmaceuticals Added to NASDAQ Biotechnology IndexGlobeNewswire(Tue May 14)
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Tue May 14)
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementsEDGAR Online(Fri May 10)
- Synergy Pharmaceuticals Reports First Quarter 2013 Financial ResultsGlobeNewswire(Thu May 9)
- SYNERGY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu May 9)
- Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on Plecanatide and SP-333 at the 15th Annual TIDES SummitGlobeNewswire(Thu May 9)
- Emerging Markets an Area of Opportunity for Global Generic Players: An Expert Analyst Gives His Take on the Generic Drug SpaceWall Street Transcript(Thu May 2)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.95 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.6 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate includes plecanatide, a guanylyl cyclase C receptor agonist that has c...
View More